BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Westphal DW, Williams SA, Leeb A, Effler PV. Continuous active surveillance of adverse events following immunisation using SMS technology. Vaccine 2016;34:3350-5. [PMID: 27206385 DOI: 10.1016/j.vaccine.2016.05.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Clothier HJ, Lawrie J, Lewis G, Russell M, Crawford NW, Buttery JP. SAEFVIC: Surveillance of adverse events following immunisation (AEFI) in Victoria, Australia, 2018. Commun Dis Intell (2018) 2020;44. [PMID: 32536336 DOI: 10.33321/cdi.2020.44.46] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Spila Alegiani S, Alfonsi V, Appelgren EC, Ferrara L, Gallo T, Alicino C, Pascucci MG, Aquilani S, Spadea A, Tafuri S, Rizzo C. Active surveillance for safety monitoring of seasonal influenza vaccines in Italy, 2015/2016 season. BMC Public Health 2018;18:1401. [PMID: 30577729 DOI: 10.1186/s12889-018-6260-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
3 Singh G, Nesaraj R, Bchara N, Kop B, Leeb A, Nissen L, Peters I, Perry D, Salter S, Lee K. Immunisation provider experiences with an automated short message service-based active surveillance system for monitoring adverse events following immunisation: A qualitative descriptive study. Digit Health 2021;7:20552076211038165. [PMID: 34616563 DOI: 10.1177/20552076211038165] [Reference Citation Analysis]
4 NNDSS Annual Report Working Group. Australia’s notifiable disease status, 2015: Annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell 2019;43. [DOI: 10.33321/cdi.2019.43.6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
5 Salter S, Singh G, Nissen L, Trentino K, Murray K, Lee K, Kop B, Peters I, Leeb A. Active vaccine safety surveillance of seasonal influenza vaccination via a scalable, integrated system in Western Australian pharmacies: a prospective cohort study. BMJ Open 2021;11:e048109. [PMID: 34103321 DOI: 10.1136/bmjopen-2020-048109] [Reference Citation Analysis]
6 Cashman P, Macartney K, Khandaker G, King C, Gold M, Durrheim DN. Participant-centred active surveillance of adverse events following immunisation: a narrative review. Int Health 2017;9:164-76. [PMID: 28582563 DOI: 10.1093/inthealth/ihx019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
7 Oliveira PMN, Lignani LK, Conceição DAD, Farias PMCM, Takey PRG, Maia MLS, Camacho LAB. Surveillance of adverse events following immunization in the late 2010s: an overview of the importance, tools, and challenges. Cad Saude Publica 2020;36Suppl 2:e00182019. [PMID: 32965327 DOI: 10.1590/0102-311X00182019] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Stockwell MS, Marchant CD, Wodi AP, Barnett ED, Broder KR, Jakob K, Lewis P, Kattan M, Rezendes AM, Barrett A, Sharma D, Fernandez N, LaRussa P. A multi-site feasibility study to assess fever and wheezing in children after influenza vaccines using text messaging. Vaccine 2017;35:6941-8. [PMID: 29089191 DOI: 10.1016/j.vaccine.2017.10.073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
9 Betancourt-Cravioto M, Cervantes-Powell P, Tapia-Conyer R, Ledlie S, Gandhi-Banga S. Improved post-marketing safety surveillance of quadrivalent inactivated influenza vaccine in Mexico using a computerized, SMS-based follow-up system. Hum Vaccin Immunother 2021;:1-4. [PMID: 34406896 DOI: 10.1080/21645515.2021.1935170] [Reference Citation Analysis]